AU Patent

AU2016329261B2 — Semifluorinated compounds for ophthalmic administration

Assigned to Novaliq GmbH · Expires 2020-05-07 · 6y expired

What this patent protects

The present invention is directed to an ophthalmic composition comprising semifluorinated compounds characterized by the general formula CF

USPTO Abstract

The present invention is directed to an ophthalmic composition comprising semifluorinated compounds characterized by the general formula CF

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

Patent Metadata

Patent number: AU2016329261B2
Jurisdiction: AU
Classification: —
Expires: 2020-05-07
Drug substance claim: No
Drug product claim: No
Assignee: Novaliq GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.